| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/13/2009 | CA2712637A1 3-(2-dimethylaminomethyl-cyclohexyl)-phenol against polyneuropathic pain |
| 08/13/2009 | CA2712593A1 Methods for treating a condition characterized by dysfunction in protein homeostasis |
| 08/13/2009 | CA2712582A1 Aryl sulfonamides as effective analgesics |
| 08/13/2009 | CA2712574A1 Polymorphic form of a [1,2,4]triazolo[4,3-a]pyridine derivative for treating inflammatory diseases |
| 08/13/2009 | CA2712080A1 Breaking immunological tolerance with a genetically encoded unnatural amino acid |
| 08/13/2009 | CA2712005A1 Pharmaceutical solid state forms |
| 08/13/2009 | CA2711937A1 Pyrido[4,3-d]pyrimidinone derivatives as kinase inhibitors |
| 08/13/2009 | CA2711871A1 N-[3-bromo-2-chloro-4-(4, 5-dihydro-1h-imidazol-2-ylmethyl)-phenyl] -methanesulfoamide as alpha-1 a adrenergic partial agonist for the treatment of incontinence |
| 08/13/2009 | CA2711778A1 Pyrrolopyrimidine derivative as pi3k inhibitor and use thereof |
| 08/13/2009 | CA2711777A1 Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer drugs |
| 08/13/2009 | CA2711726A1 Novel imidazolinylmethyl aryl sulfonamides |
| 08/13/2009 | CA2711724A1 Novel imidazolinylmethyl aryl sulfonamides |
| 08/13/2009 | CA2711582A1 Spirocyclic heterocycles, medicaments containing said compounds, use thereof and processes for the preparation thereof |
| 08/13/2009 | CA2711414A1 Oral care product and methods of use and manufacture thereof |
| 08/13/2009 | CA2711413A1 Alendronate formulations, method of making and method of use thereof |
| 08/13/2009 | CA2711399A1 3-substituted sulfonylpiperidine derivative |
| 08/13/2009 | CA2711078A1 Furo- and thieno[3,2-c] pyridines |
| 08/13/2009 | CA2710650A1 Oral care product and methods of use and manufacture thereof |
| 08/13/2009 | CA2710579A1 Beverage comprising arginine |
| 08/13/2009 | CA2710462A1 Novel pyridinones and pyridazinones |
| 08/13/2009 | CA2708668A1 Novel vaccines against multiple subtypes of dengue virus |
| 08/13/2009 | CA2707084A1 Oral care product and methods of use and manufacture thereof |
| 08/13/2009 | CA2706812A1 Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof |
| 08/13/2009 | CA2706512A1 Compositions and devices |
| 08/13/2009 | CA2706505A1 Effervescent compositions |
| 08/13/2009 | CA2706486A1 Oral care product and methods of use and manufacture thereof |
| 08/13/2009 | CA2706481A1 Oral care regimen |
| 08/13/2009 | CA2706351A1 Arginine salts and their uses for the treatment of illnesses in the oral cavity |
| 08/13/2009 | CA2706082A1 Nitric oxide donor compounds |
| 08/12/2009 | EP2088206A2 Induction of the mitochondrial permeability transition |
| 08/12/2009 | EP2088150A1 Fused pyrrolocarbazoles and methods for the preparation thereof |
| 08/12/2009 | EP2088149A1 Pharmacologically active n,n'-substituted 3,7-diazabicyclo ý3.3.1¨nonanes, pharmaceutical compositions based thereon and a method for the use thereof |
| 08/12/2009 | EP2088148A2 "Process for the preparation of solifenacin" |
| 08/12/2009 | EP2088147A1 Dibenzo-condensed azepine, diazepine, oxazepine and thiazepine derivatives as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| 08/12/2009 | EP2088146A2 Polymorphs of 3-[(2-{[4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propion acid-ethyl ester |
| 08/12/2009 | EP2088143A1 Novel inhibitors of mycobacterium tuberculosis complex cytochrome P450 CYP121 |
| 08/12/2009 | EP2088141A2 Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same |
| 08/12/2009 | EP2087912A1 ENVIRONMENT-RESPONDING siRNA CARRIER USING DISULFIDE-BRIDGED POLYMERIC MICELLE |
| 08/12/2009 | EP2087909A1 Formulation of an injectable paracetamol solution, method of manufacturing and packaging such a solution and device for packaging such a solution |
| 08/12/2009 | EP2087908A1 Antibodies to opgl |
| 08/12/2009 | EP2087906A1 Proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines |
| 08/12/2009 | EP2087897A1 Method for producing apyrogenic immunomodulator |
| 08/12/2009 | EP2087896A1 Topical compositions comprising colostrum, folates and honey of rose for the treatment of disorders of the oral cavity |
| 08/12/2009 | EP2087894A1 Formulations comprising PIECID and RESVERATROL able to prevent and inhibit lipid peroxidation |
| 08/12/2009 | EP2087893A1 Compositions comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and processes for preparing them |
| 08/12/2009 | EP2087892A2 (S,S) reboxetine for treating age associated learning and mental disorders |
| 08/12/2009 | EP2087891A2 Pharmaceutical compositions for treating lymphoma |
| 08/12/2009 | EP2087890A1 Sustained release preparation for tissue regeneration therapy |
| 08/12/2009 | EP2087889A2 Controlled release oral tablet having a unitary core |
| 08/12/2009 | EP2087888A1 Adenosine a1 receptor antagonists for the treatment of alkalosis |
| 08/12/2009 | EP2087887A1 Highly absorbable composition for oral administration containing oxidized coenzyme q10 |
| 08/12/2009 | EP2087886A1 Therapeutic agent for rheumatoid arthritis |
| 08/12/2009 | EP2087885A1 Use of urokinase inhibitors for the treatment and /or prevention of neuropathological diseases |
| 08/12/2009 | EP2087884A2 Extended Release Gliclazide Formulations |
| 08/12/2009 | EP2087883A1 Stabilised supersaturated solid solutions of steroidal drugs |
| 08/12/2009 | EP2087882A1 Drug microparticles |
| 08/12/2009 | EP2087115A2 Blocking of gene expression in eukaryotic cells |
| 08/12/2009 | EP2086999A1 Inhibitors for disrupting the interaction of ubiquitination related enzymes and uses thereof |
| 08/12/2009 | EP2086995A1 Hepatitis c virus inhibitors |
| 08/12/2009 | EP2086991A1 CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
| 08/12/2009 | EP2086990A2 Novel nucleotide analogues as percursor molecules for antivirals |
| 08/12/2009 | EP2086983A2 Fused ring compounds for inflammation and immune-related uses |
| 08/12/2009 | EP2086982A1 Hcv ns3 protease inhibitors |
| 08/12/2009 | EP2086981A1 Compounds for inhibiting mitotic progression |
| 08/12/2009 | EP2086980A1 Macrocyclic peptides as hepatitis c virus inhibitors |
| 08/12/2009 | EP2086979A2 Imidazoý1,2-b¨pyridazine and pyrazoloý1,5-a¨pyrimidine derivatives and their use as protein kinase inhibitors |
| 08/12/2009 | EP2086978A1 Amorphous form of n-{2-fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo [1,5-a]pyrimidin-7-yl]-phenyl-n-methyl-acetamide |
| 08/12/2009 | EP2086975A2 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods |
| 08/12/2009 | EP2086972A2 Compounds modulating c-fms and/or c-kit activity and uses therefor |
| 08/12/2009 | EP2086971A1 Crystalline forms of thiazolidinedione derivative and its manufacturing method |
| 08/12/2009 | EP2086970A2 2-(pyrazin-2-yl)-thiazole and 2-(1h pyrazol-3-yl)-thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders |
| 08/12/2009 | EP2086969A1 3-cyano-5-thiazaheteroaryl-dihydropyridine and the use thereof for the treatment of cardiovascular diseases |
| 08/12/2009 | EP2086968A1 5-hydroxymethyl-oxazolidin-2-one derivatives |
| 08/12/2009 | EP2086965A1 Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
| 08/12/2009 | EP2086964A2 Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk |
| 08/12/2009 | EP2086963A2 Hepatitis c virus inhibitors |
| 08/12/2009 | EP2086962A1 (r) -5-methyl-4, 5-dihydro- pyrazole-1, 5-dicarboxylic acid 1- [( 4 -chlorophenyl) amide 5-{ [2-fluoro-4- (2-oxo-2h-pyridin-1-yl) -phenyl]amide) as a factor xa inhibitor |
| 08/12/2009 | EP2086961A1 Heterocyclic derivatives as cetp inhibitors |
| 08/12/2009 | EP2086960A1 Novel inhibitors of glutaminyl cyclase |
| 08/12/2009 | EP2086959A1 Substituted 2-imidazoles as modulators of the trace amine associated receptors |
| 08/12/2009 | EP2086958A2 Substituted-quinoxaline-type-piperidine compounds and the uses thereof |
| 08/12/2009 | EP2086957A1 Sulphamate benzothiophene derivatives |
| 08/12/2009 | EP2086956A1 Inhibitors of ikk- beta serine-threonine protein kinase |
| 08/12/2009 | EP2086954A1 Composition comprising (-)-delta 9-trans-tetrahydrocannabinol |
| 08/12/2009 | EP2086951A1 Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
| 08/12/2009 | EP2086947A1 Pyrimidines and their use as cxcr2 receptor antagonists |
| 08/12/2009 | EP2086943A1 Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| 08/12/2009 | EP2086942A2 Novel compounds |
| 08/12/2009 | EP2086941A1 Antibacterial quinoline derivatives |
| 08/12/2009 | EP2086940A1 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol |
| 08/12/2009 | EP2086939A2 Pyridine carboxamides as 11-beta-hsd1 inhibitors |
| 08/12/2009 | EP2086938A1 Organic compounds |
| 08/12/2009 | EP2086937A1 Novel triphenylamine derivatives for use as fluorophores in biology, in particular for two-photon microscopy |
| 08/12/2009 | EP2086935A1 Substituted sulfonamide derivatives for use as bradykinin 1 receptor modulators |
| 08/12/2009 | EP2086933A2 Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| 08/12/2009 | EP2086926A2 Crystalline forms of tigecycline and processes for preparation thereof |
| 08/12/2009 | EP2086925A1 1,4 diamino bicyclic retigabine analogues as potassium channel modulators |
| 08/12/2009 | EP2086924A1 [f-18]-labeled l-glutamic acid, [f-18]-labeled l-glutamine, derivatives thereof and use thereof and processes for their preparation |
| 08/12/2009 | EP2086922A2 Isolated hydroxy and n-oxide metabolites and derivatives of o-desmethylvenlafaxine and methods of treatment |
| 08/12/2009 | EP2086643A1 Compounds which potentiate ampa receptor and uses thereof in medicine |